RxDoctor Payments Data

John Paul Armilio, MD

Family Medicine · Kansas City, MONPI 1386873743

Payments from drug & device makers

$664in general payments, 2019–2025

Across 14 payments — averaging $47.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Foundation Medicine, Inc.$277
  • Pfizer$166
  • Inari Medical, Inc.$136
  • Boston Scientific$83
  • E.r. Squibb & Sons, L.L.C.$2

What the payments were for

  • Speaking & faculty fees$27742%
  • Food & beverage$38558%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$664 in reported general payments places this provider in the 55th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$867,605
Medicare patients
1,429
Services billed
7,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$36,264
EntrestoSacubitril/Valsartan58$11,085
JardianceEmpagliflozin14$6,247
XareltoRivaroxaban34$5,963
TradjentaLinagliptin36$4,859
TrintellixVortioxetine Hydrobromide19$2,910
Atorvastatin Calcium368$2,058
Diltiazem 24hr Er (La)Diltiazem Hcl45$1,328
Carbamazepine54$1,200
Tamsulosin Hcl222$1,176
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$1,008
Duloxetine Hcl48$897
Sevelamer Carbonate28$889
Metoprolol Succinate113$859
Insulin Lispro Kwikpen U-100Insulin Lispro17$847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$166$36,264150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →